New angioplasty procedure improves blood flow in blocked arteries to extremities

July 24, 2012

Patients with blocked arteries to their extremities, known as peripheral artery disease (PAD) or critical limb ischemia (CLI), may now find relief from lower leg pain and wounds caused by impaired leg artery circulation with the previously unproven therapy, percutaneous transluminal angioplasty (PTA). The XCELL trial results now available in Catheterization and Cardiovascular Interventions, a journal published by Wiley on behalf of the Society for Cardiovascular Angiography and Interventions (SCAI), reports that infrapopliteal nitinol stenting to treat CLI is safe and effective in improving wound healing, providing pain relief, and promoting amputation-free survival.

PAD is a disorder in which narrowed blood vessels restrict blood flow in the limbs. CLI affects close to 30 million people in Europe and North America, with most experiencing pain and ulcers with or without gangrene in the legs. Experts agree that current treatment options should aim to relieve pain, heal ulcers, prevent , improve quality of life and prolong survival. Previous research, however, show rates are as high 40% in CLI patients in the first year following their diagnosis, with approaching 20%. Moreover, prior studies estimate that 160,000 amputations due to PAD are performed each year in the U.S., of which a 25% reduction could save $29 billion in according to the Sage Group.

"With the , we expect the incidence of diabetes to rise as well, and as these patients age this could sharply increase rates of CLI," explains Dr. Krishna J. Rocha-Singh, MD, FSCAI with Prairie Education & Research Cooperative in Springfield, Ill. "It is essential that we identify less invasive treatment strategies that are safe and effective in improving vascular disease."

One promising procedure for improving CLI outcomes is PTA with stenting of the infrapopliteal arteries. The multi-center trial of the "XpertTM Nitinol Stenting For Critically IschEmic Lower Limbs" (XCELL) evaluates the safety and effectiveness of this device in patients with CLI. The Xpert stent is manufactured by Abbott, a global health care company. The device was evaluated in 120 CLI patients with infrapopliteal lesions of 4-15 cm in length. A total of 140 limbs and 212 implanted devices were included in the study, with 12-month amputation-free survival (AFS), limb salvage, wound healing and pain relief determining the success of the procedure.

Results reveal that 12-month AFS was 78%. Further analysis confirmed that according to baseline Rutherford classes 4, 5, and 6, the 12-month AFS rates were 100%, 77%, 55%, respectively; freedom from major amputation were 100%, 91% and 70%, respectively. The investigators also determined that the 12-month freedom from major amputation rate and clinically driven target lesion revascularization were 90% and 70%, respectively. Six-month and 12-month wound-healing rates were 49% and 54%, respectively. Moreover, Rutherford class 4 patients had significant pain relief through 12 months.

"Our XCELL trial findings confirm that infrapopliteal nitinol stenting is safe and effective in treating CLI patients," concludes Dr. Rocha-Singh. "While there were a few major adverse events, such as death, heart attack, or major amputation that occurred in the first 30 days, at the first year post-procedure, limb preservation, wound healing and pain relief rates were excellent." The authors also point out that the 12-month with nitinol was similar to the more invasive open surgery.

Explore further: Research offers new hope for peripheral artery disease sufferers

More information: "Major Adverse Limb Events and Wound Healing Following Infrapopliteal Artery Stent Implantation in Patients with Critical Limb Ischemia: The XCELL Trial." Krishna J. Rocha-Singh, Michael Jaff, James Joye, John Laird, Gary Ansel, Peter Schneider on behalf of the VIVA Physicians. Catheterization and Cardiovascular Interventions; Published Online: July 24, 2012. DOI: 10.1002/ccd.24485

Related Stories

Research offers new hope for peripheral artery disease sufferers

May 2, 2012
Research led by vascular surgeons at Dartmouth-Hitchcock may offer new hope to sufferers of peripheral artery disease, the cause of nearly 60,000 lower-limb amputations annually, through the use of a patient's own stem cells.

Angioplasty may be risky for those with poor leg circulation

May 9, 2012
(HealthDay) -- People with peripheral artery disease have an increased short- and long-term risk of death after undergoing a procedure to open clogged heart arteries, a new study finds.

Recommended for you

Could this protein protect people against coronary artery disease?

November 17, 2017
The buildup of plaque in the heart's arteries is an unfortunate part of aging. But by studying the genetic makeup of people who maintain clear arteries into old age, researchers led by UNC's Jonathan Schisler, PhD, have identified ...

Raising 'good' cholesterol fails to protect against heart disease

November 16, 2017
Raising so-called 'good' cholesterol by blocking a key protein involved in its metabolism does not protect against heart disease or stroke, according to a large genetic study of 150,000 Chinese adults published in the journal ...

New model estimates odds of events that trigger sudden cardiac death

November 16, 2017
A new computational model of heart tissue allows researchers to estimate the probability of rare heartbeat irregularities that can cause sudden cardiac death. The model, developed by Mark Walker and colleagues from Johns ...

Popular e-cigarette liquid flavorings may change, damage heart muscle cells

November 16, 2017
Chemicals used to make some popular e-cigarette liquid flavorings—including cinnamon, clove, citrus and floral—may cause changes or damage to heart muscle cells, new research indicates.

Possible use for botulinum toxin to treat atrial fibrillation

November 16, 2017
From temporarily softening wrinkles to easing migraines, botulinum toxin has become a versatile medical remedy because of its ability to block nerve signals that can become bothersome or risky.

Proteome of the human heart mapped for the first time

November 15, 2017
A healthy heart beats about two billion times during a lifetime, thanks to the interplay of more than 10,000 proteins. Researchers from the Max Planck Institute of Biochemistry (MPIB) and the German Heart Centre at the Technical ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.